Aventis Alvesco For Asthma Is One Of Five NDA/BLA Filings Planned For 2003
Aventis is planning a third quarter NDA filing for the asthma therapy Alvesco, one of up to five novel agents the company expects to reach the filing stage by early 2004
Aventis is planning a third quarter NDA filing for the asthma therapy Alvesco, one of up to five novel agents the company expects to reach the filing stage by early 2004